After the NJ Cannabis Regulatory Commission, or CRC, voted to renew Curaleaf’s five annual licenses, reversing a decision from last Thursday. Alliance Global Partners analyst Aaron Grey aid the firm sees this as a "win for not only [Curaleaf], but other MSOs and the industry, as broad interpretations of rules cannot be used as justification to shut down operations." For Curaleaf, the company will be able to continue to service the New Jersey adult-use market as "the leader with a 22% share" and there will be no disruption in operations, said the firm, which reiterates a Buy rating and C$8 price target on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CURLF:
- Curaleaf spikes over 7% after NJ CRC Board reverses, okays adult use renewals
- Curaleaf says NJ CRC Board reverses, fully approves adult use renewals
- Curaleaf says working with New Jersey to ensure license renewal
- Curaleaf price target lowered to $8 from $11 at Alliance Global Partners
- NJ cannabis vote ‘crushing blow’ for Curaleaf, says Wedbush